Overview

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Cediranib
Lomustine